1-6 of 6
Richard T. Penson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Ryan B. Corcoran, Khanh T. Do, Jeong E. Kim, James M. Cleary, Aparna R. Parikh, Oladapo O. Yeku, Niya Xiong, Colin D. Weekes, Jennifer Veneris, Leanne G. Ahronian, Gianluca Mauri, Jun Tian, Bryanna L. Norden, Alexa G. Michel, Emily E. Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J. Fetter, Joan S. Brugge, Helen Chen, Naoko Takebe, Richard T. Penson, Dejan Juric, Keith T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, Ursula A. Matulonis, Joyce F. Liu, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1739–1749.
https://doi.org/10.1158/1078-0432.CCR-23-3135
Published: 01 May 2024
View articletitled, Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Open the PDF for Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew, Jae-Weon Kim, Richard T. Penson, David M. O'Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock-Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Gal-Yam, Daliah Tsoref, Jae-Hoon Kim, Benoit You, Maja De Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee, for the MEDIOLA Investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 50–62.
https://doi.org/10.1158/1078-0432.CCR-23-2249
Published: 05 January 2024
View articletitled, Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Open the PDF for Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study in another window
Includes: Supplementary data
Journal Articles

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study

Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, Harry J. Long, III, Andrés Poveda, Lisa M. Landrum, Mario M. Leitao, Jubilee Brown, Thomas J.A. Reid, Helen E. Michael, David H. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5480–5487.
https://doi.org/10.1158/1078-0432.CCR-15-1346
Published: 14 December 2015
View articletitled, Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Open the PDF for Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study in another window
Includes: Supplementary data
Journal Articles

Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy

Mory Nouriani, Afshin Bahador, Jonathan S. Berek, Joan P. Cheng, Dennis S. Chi, William A. Cliby, Giuseppe Del Priore, Mark K. Dodson, Bridgette D. Duggan, David M. Gershenson, Scott E. Lentz, Richard T. Penson, William R. Robinson, Mildred Rodriguez, Lynda D. Roman, Mimi C. Yu, Karen Zempolich, Louis Dubeau
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (8): 2681–2686.
https://doi.org/10.1158/1078-0432.CCR-0523-03
Published: 20 April 2004
View articletitled, Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy
Open the PDF for Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy in another window
Journal Articles

Overexpression of MAGE/GAGE Genes in Paclitaxel/Doxorubicin-resistant Human Cancer Cell Lines

Zhenfeng Duan, Yifei Duan, Diana E. Lamendola, Rushdia Z. Yusuf, Rizwan Naeem, Richard T. Penson, Michael V. Seiden
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2778–2785.
Published: 01 July 2003
View articletitled, Overexpression of MAGE/GAGE Genes in Paclitaxel/Doxorubicin-resistant Human Cancer Cell Lines
Open the PDF for Overexpression of MAGE/GAGE Genes in Paclitaxel/Doxorubicin-resistant Human Cancer Cell Lines in another window
Journal Articles

Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype

Zhenfeng Duan, Aynn J. Feller, Richard T. Penson, Bruce. A. Chabner, Michael V. Seiden
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (11): 3445–3453.
Published: 01 November 1999
View articletitled, Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype
Open the PDF for Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype in another window